Journals / Retina-Vitreus / 2011 / Cilt: 19 - Sayı: 2

Vogt-koyanagi-harada disease

Vogt koyanagi harada hastalığı

Pages
148–151
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

VKH should be kept in mind especially in patients with bilateral visual loss following headache.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:An 18-year-old female presented with bilateral visual loss following severe headache.
📊
Key Findings & Data:She had bilateral serous retinal detachment in the fundus examination, multiple pinpoint leakage in fundus fluoresein angiography, and choroidal thickening in ultrasonography.
💡
Conclusion & Impact:VKH should be kept in mind especially in patients with bilateral visual loss following headache.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

An 18-year-old female presented with bilateral visual loss following severe headache. She had bilateral serous retinal detachment in the fundus examination, multiple pinpoint leakage in fundus fluoresein angiography, and choroidal thickening in ultrasonography. As there was no history of ocular trauma or previous ocular surgery and the systemic evaluation was normal, the patient was diagnosed with probable Vogt-Koyanagi-Harada (VKH) disease. The retina was completely attached by the treatment of steroid and cyclophosphamide combination in the first week. The ocular and systemic effects might be improved by appropriate treatment in VKH, which is a rare cause of uveitis in Turkey. VKH should be kept in mind especially in patients with bilateral visual loss following headache.

Özet

On sekiz yaşında bayan hasta, şiddetli baş ağrısını takiben her iki gözünde görme kaybı ile başvurdu. Muayenesinde bilateral seröz retina dekolmanı, fundus fluoresein anjiografisinde multifokal noktasal sızıntı ve subretinal göllenme, ultrasonografisinde koroidde kalınlaşma görülen olgu, altta yatan sistemik bir hastalık saptanmaması, oküler travma veya cerrahi öyküsü bulunmaması üzerine olası Vogt Koyanagi Harada (VKH) olarak değerlendirildi. Sistemik steroid ve siklofosfamid başlanan hastada, tedaviden sonraki 1. haftada retina dekolmanının tamamen düzeldiği görüldü. Ülkemizde az görülen üveit nedenlerinden biri olan VKH hastalığında uygun tedavi ile oküler ve sistemik tutulum düzelebilmektedir. Özellikle baş ağrısını takiben gelişen bilateral görme kayıplarında VKH tanısını akla getirmek gereklidir.

🔖

Cite This Article

ÇETİN, E. N., YALDIZKAYA, F., YAYLALI, V., YILDIRIM, C. (2011). Vogt-koyanagi-harada disease. Retina-Vitreus, Cilt: 19 - Sayı: 2, 148–151. https://ajindex.com/articles/305120

References (16)

  1. Andreoli CM, Foster CS.: Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46:111-122
  2. Tugal-Tutkun I, Ozyazgan Y, Akova YA et al.: The spectrum of Vogt-Koyanagi-Harada disease in Turkey: VKH in Turkey. Int Ophthalmol. 2007;27:117-123
  3. Read RW, Holland GN, Rao NA et al.: Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652
  4. Yamaki K, Hara K, Sakuragi S.: Application of revised diagnostic criteria for vogt-koyanagi-harada disease in Japanese patients. Jpn J Ophthalmol. 2005;49:143-148
  5. Yang P, Ren Y, Li B et al.: Clinical characteristics of Vogt-Koyanagi- Harada syndrome in Chinese patients. Ophthalmology. 2007;114:606-614
  6. Sukavatcharin S, Tsai JH, Rao NA.: Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol. 2007;27:143-148
  7. Chee SP, Jap A, Bacsal K.: Spectrum of Vogt-Koyanagi-Harada disease in Singapore. Int Ophthalmol. 2007;27:137-142
  8. Murthy SI, Moreker MR, Sangwan VS et al.: The spectrum of Vogt-Koyanagi-Harada disease in South India. Int Ophthalmol. 2007;27:131-136
  9. Fang W, Yang P.: Vogt-koyanagi-harada syndrome. Curr Eye Res. 2008;33:517-523
  10. Rao NA.: Treatment of Vogt-Koyanagi-Harada disease by corticosteroids and immunosuppressive agents. Ocul Immunol Inflamm. 2006;14:71-72
  11. Read RW, Yu F, Accorinti M et al.: Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2006;142:119-124
  12. Yamanaka E, Ohguro N, Yamamoto S et al.: Evaluation of pulse corticosteroid therapy for vogt-koyanagi-harada disease assessed by optical coherence tomography. Am J Ophthalmol. 2002;134:454-456
  13. Paredes I, Ahmed M, Foster CS.: Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006;14:87-90
  14. Couch SM, Bakri SJ.: Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol. 2009;3:41-47
  15. Chee SP, Jap A, Bacsal K.: Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol. 2009;147:154-161
  16. Kitaichi N, Horie Y, Ohno S.: Prompt therapy reduces the duration of systemic corticosteroids in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol. 2008;246:1641-1642.